Jubilant Ingrevia Ltd

- Recent capital expenditures have been primarily funded through internal accruals. - The company incurred INR59 crore in capex during the latest quarter and INR109 crore year-to-date. - Planned capex for FY 2026 is approximately INR600 crore, which will also be supported by internal accruals. - There is no mention of any current or planned fundraising through debt or equity in the disclosed earnings call transcript. - The net debt-to-EBITDA ratio stands at 1.24x, indicating manageable leverage. - Overall, Jubilant Ingrevia currently relies on internal accruals for funding its growth and capex without any announced plans for debt or equity fundraising.

- INR59 crore capex incurred in the quarter, primarily towards the upcoming CDMO Agro plant at Bharuch and new multipurpose facility in Gajraula. - Planned investment of approximately INR600 crore in FY '26, funded largely through internal accruals. - Commissioning of $300 million Agro-Innovator CDMO project expected by Q4 FY '26. - New boiler commissioning at Bharuch scheduled for Q3 FY '26 to enhance operational efficiency. - Debottlenecking capacity in existing plants by 15-20% to support new CDMO and Fine Chemical volumes. - Groundbreaking of new multipurpose plant at Gajraula to add flexibility and capacity in CDMO portfolio. - Development of a state-of-the-art Semiconductor R&D facility in Greater Noida, aimed at innovation in semiconductor chemicals. - Plans for a pilot plant in semiconductor chemicals in near future, details to be announced in due course.

- Expecting steady growth across segments with pipeline of 100+ active opportunities and 50+ products under development. - Anticipate INR1,200 crore peak annual revenue from 10+ new CDMO and Fine Chemical molecules, contributing revenue from FY '26 and ramping up over 2-3 years. - FY '26 includes launch of 18 new products aligned with market needs. - Nutrition segment volume growth seen in vitamin B3 and B4, with strong traction in cosmetic grade sales. - Anti-dumping duties on China creating new export opportunities, especially for choline chloride in Europe. - Capacity expansions, including new multipurpose plant at Gajraula and semiconductor R&D facility, planned to support growth from 2026-27 onward. - Ongoing cost optimization and lean savings program supporting margin expansion amid pricing pressures. - Renewable energy integration and operational efficiencies expected to reduce energy costs further. - Overall confident in sustaining top line and margin growth over coming quarters.

- Expectation to achieve INR1,200 crore peak annualized revenue from 10+ new CDMO molecules in 2-3 years, including a major $300 million (INR500 crore annual) contract starting early next year. - EBITDA growth supported by cost optimization initiatives, with lean savings program targeting INR100 crore per year ongoing and robust. - Specialty Chemicals segment margins steady at ~26%, Nutrition segment margins expected to improve from current 12%-14% to 16%-18% with mix changes. - Overall EBITDA grew 8% YoY in Q2 FY '26; half-year EBITDA increased 18%, PAT surged 34% YoY. - Target INR2,000 crore EBITDA by FY 2030 from CDMO and related businesses. - Continuous cost control and efficiency programs expected to enhance margins. - R&D investments increasing, especially in Specialty and Nutrition segments, supporting future product launches and revenue growth. - Renewable energy initiatives and new boiler commissioning to reduce energy costs and improve operating profits.

- The company has expanded its opportunity funnel to over 100+ active opportunities, up from 70 in Q1, indicating a healthy and growing orderbook. - There are 10 molecules already signed in the CDMO business, with one molecule already supplied and others in various stages of supply ramp-up. - Another 10+ opportunities are in advanced stages of discussion, expected to convert into confirmed orders in coming quarters. - For the new CDMO molecules, revenues typically ramp up from 15-20% in Year 1, to 40-60% in Year 2, and reach peak (80-100%) by Year 3. - Early order bookings following EU anti-dumping duties (e.g., choline chloride) have started and the pipeline looks healthy for Nutrition business. - The $300 million Agro-Innovator project is on track for Q4 commissioning, expected to contribute to order fulfillment and revenues from 2026 onwards.